Much as expected, management remains positive

EBITDA of USD 31m (ABGSCe and cons at USD 30-31m). ~11% downside cons Q4 EBITDA management remains positive. Share to trade flat vs. peers.

Rates up ~70% YTD trumps current weakness

Himalaya Shipping (Sell, TP: NOK67.00) - Markets hinder near-term potential

Despite Himalaya Shipping now having a fully delivered top-modern fleet, with limited need for further capital investment, we remain concerned about what we view as material headwinds for dry bulk in the months ahead. Moreover, asset values are at 15-year highs and are unsupported by current freight markets. Hence, we find the risk skewed to the downside, with asset values most likely to correct lower. We have downgraded to SELL (HOLD) and cut our target price to NOK67 (91).

Sinch (Buy, TP: SEK33.00) - Remains a BUY on valuation

Adjusted for a one-off, organic gross profit growth disappointed and the outlook for Q4 and the start of 2025 remains weak. We still see a strong underlying market and reiterate our BUY due to an attractive valuation. We have lowered our target price to SEK33 (37).

Genmab (Buy, TP: DKK2500.00) - Still awaiting CD-38 decision

Q3 revenue missed our expectations, but operating profit exceeded due to lower operating costs. 2024 guidance for revenue was raised to DKK21.1bn–21.7bn; for opex was narrowed downwards to DKK14.1bn–14.4bn (due to portfolio prioritisation); and for operating profit, narrowed to the high end of DKK6.2bn–7.1bn. Investor focus was on JNJ’s upcoming opt-in decision (data submission expected end-2024). We reiterate our BUY and DKK2,500 target price.

XXL ASA (No_rec, TP: NOK) - Recommendation and target price withdrawn

XXL reported weak Q3 results and announced a contemplated NOK600m fully underwritten rights issue. Given DNB Markets’ role in the contemplated rights issue, we have withdrawn our recommendation and target price.